Floatz logo

Cymbalta

Hemophilic Arthropathy

Hospital for Special Surgery, New YorkPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hemophilic Arthropathy cohort.

Asset / SponsorPhaseRating
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Hospital for Special Surgery, New York
Phase 4BB
Rofecoxib
Tremeau Pharmceuticals, Inc.
Phase 3B
AUTOLOGOUS CONDITIONED PLASMA
Tri-Service General Hospital
N/AD

Same molecule, other indications

Cymbalta is also rated in:

Pain, AcuteDormant
BB
Indicative ·
69 / 100
View asset →
chronic pain syndromeDormant
BB
Indicative ·
65 / 100
View asset →
schizophreniaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →